Biosimilars—Emerging Role in Nephrology

What is it about?

The FDA defines a “biosimilar” agent as a biologic that is highly similar to the reference or originator biologic product notwithstanding minor differences in clinically inactive components with no clinically meaningful differences in terms of the safety, purity, and potency. The advantage of biosimilars is that they are usually about 15-30% less expensive than the reference product, which results in system-wide cost savings and increased patient access.

Featured Image